32 completed, 3 recruiting, 1 not yet recruiting, 1 terminated. 38 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 38 | Completed 32, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Not yet recruiting 1 |
Follow Dermatomycoses: new trials by email Literature Review of Dermatomycoses trials Research Report on Dermatomycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation, Placebo topical formulation - Tinea Pedis | Phase 1 | Recruiting | Sinomune Pharmaceutical Co., Ltd | 64 | 2026-07-21 | 2026-08-04 |
| Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor Topical 1 % clotrimazole twice daily 2 weeks, Oral itraconazole 200mg daily for 5 days - Pityriasis Versicolor | Phase 1 / Phase 2 | Not yet recruiting | Combined Military Hospital Abbottabad | 86 | 2026-02-02 | 2026-01-12 |
| A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor 20% Cassia alata cream - Tinea Versicolor, Pityriasis Versicolor | Phase 1 | Recruiting | The University of The West Indies | 20 | 2025-03-01 | 2025-11-19 |
| Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis ISOtretinoin 10 MG, excimer light, Itraconazole 200 mg - Onychomycosis | Phase 1 | Recruiting | Zagazig University | 36 | 2024-07-12 | 2026-04-23 |
| A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor. Ketoconazole Shampoo, 2%, Ketoconazole Shampoo, 2% (Reference Standard), Placebo - Tinea Versicolor | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 430 | 2023-12-04 | 2024-03-12 |
| Pilot Study of Swift Microwave Device for Onychomycosis Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail | Phase 1 / Phase 2 | Completed | Mediprobe Research Inc. | 39 | 2023-03-27 | 2024-11-18 |
| A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis ATB1651, 2 mg/mL, ATB1651, 5 mg/mL, ATB1651, 10 mg/mL - Onychomycosis | Phase 1 | Completed | AmtixBio Co., Ltd. | 30 | 2022-03-04 | 2023-10-11 |
| Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis itraconazole, terbinafine - Onychomycosis | Phase 1 | Completed | Combined Military Hospital Abbottabad | 100 | 2022-03-01 | 2022-10-19 |
| Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor Fluconazole, Itraconazole - Tinea Versicolor | Phase 1 | Completed | Combined Military Hospital Abbottabad | 164 | 2022-03-01 | 2023-05-17 |
| Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis UHE-103 Cream, Naftin (naftifine hydrochloride) Cream - Tinea Cruris, Tinea Pedis | Phase 1 | Completed | Therapeutics, Inc. | 42 | 2022-02-17 | 2024-04-10 |
| Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis SKX-16 (Luliconazole 10% Solution) - Onychomycosis of Toenail | Phase 1 | Completed | SATO Pharmaceutical Co., Ltd. | 19 | 2021-09-22 | 2026-08-21 |
| Alpha-bisabolol for Onychomycosis Treatment Drug recommended by the Brazilian Society of Dermatology, Alpha bisabolol product and laser, Alpha bisabolol product - Onychomycosis | Phase 1 | Completed | Universidade do Vale do Sapucai | 60 | 2020-06-01 | 2021-06-30 |
| Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions Griseofulvin 500 mg, Griseofulvin 250 mg, Reference Griseofulvin 500 mg - Antifungal Agents | Phase 1 | Completed | GlaxoSmithKline | 36 | 2020-01-13 | 2020-12-28 |
| Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel Oxiconazole Nitrate Cream 1%, Oxiconazole nitrate SLNs loaded gel. - Tinea | Phase 1 | Completed | Minia University | 28 | 2018-07-16 | 2019-01-30 |
| A Study of the Systemic Absorption of MOB015B MOB015B - Onychomycosis | Phase 1 | Completed | Moberg Pharma AB | 20 | 2017-12-16 | 2018-05-03 |
| A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers Lozanoc 50mg, Sporanox 100mg - Superficial Mycoses, Dermatomycoses | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 24 | 2015-07-01 | 2016-03-04 |
| Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Naftifine Hydrochloride Gel 2%, Naftin® Gel 2%, Placebo Topical Gel - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1519 | 2014-06-27 | 2018-09-06 |
| Rituximab for Anti-cytokine Autoantibody-Associated Diseases Rituximab - Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 7 | 2014-04-29 | 2026-10-26 |
| Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis Naftifine Hydrochloride Cream 2%, Naftin® (Naftifine Hydrochloride) Cream 2%, Placebo Topical Cream - Tinea Pedis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 890 | 2013-08-01 | 2017-05-09 |
| Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients ME1111 solution, Vehicle Solution - Onychomycosis | Phase 1 | Completed | Meiji Seika Pharma Co., Ltd. | 24 | 2013-03-01 | 2013-12-17 |
Showing 20 of 38. Sign in to see all of them.
Onychomycosis (17) · Tinea Pedis (13) · Tinea Versicolor (4) · Histoplasmosis (2) · Mycoses (2) · Tinea (2) · Blastomycosis (1) · Candidiasis (1) · Candidiasis, Chronic Mucocutaneous (1) · Communicable Diseases (1) · Immune System Diseases (1) · Onycholysis (1) · Pulmonary Alveolar Proteinosis (1) · Rare Diseases (1)
Bacterial Infections and Mycoses (38) · Infections (38) · Skin Diseases (38) · Skin Diseases, Infectious (38) · Skin and Connective Tissue Diseases (38) · Mycoses (36) · Tinea (29) · Nail Diseases (17) · Pathological Conditions, Signs and Symptoms (15) · Foot Dermatoses (13) · Foot Diseases (13) · Pruritus (13) · Signs and Symptoms (13) · Skin Manifestations (13)
Itraconazole (6) · naftifine (4) · Terbinafine (3) · butenafine (3) · Sodium Dodecyl Sulfate (2) · Tablets (2) · Capsules (1) · Clotrimazole (1) · Fluconazole (1) · Griseofulvin (1) · Isotretinoin (1) · Laser Therapy (1) · Lasers (1) · Reference Standards (1) · Rituximab (1)
Sun Pharmaceutical Industries, Inc. (8) · Combined Military Hospital Abbottabad (3) · Stiefel, a GSK Company (3) · Pfizer (2) · AmtixBio Co., Ltd. (1) · Boryung Pharmaceutical Co., Ltd (1) · Galderma R&D (1) · GlaxoSmithKline (1) · Mediprobe Research Inc. (1) · Meiji Seika Pharma Co., Ltd. (1) · Minia University (1) · Moberg Pharma AB (1) · National Center for Research Resources (NCRR) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) (1)
United States (17) · Egypt (2) · Pakistan (2) · Australia (1) · Belize (1) · Brazil (1) · Canada (1) · China (1) · Hong Kong (1) · India (1) · Jamaica (1) · New Zealand (1) · South Korea (1) · Taiwan (1)
Natalie Yantovskiy (2) · Aditya Gupta, MD,PhD (1) · Alexa B. Kimball, MD, MPH (1) · Brent Clary, CCRC (1) · Christa S Zerbe, M.D. (1) · Chun Wah M. Yuen (1) · Craig Sprenger, MD (1) · David Gratton, MD (1) · Debra Breneman, MD (1) · Eduardo Tschen, MD (1) · Eric M Morrel, PhD (1)